IONIS PHARMACEUTICALS INC
NASDAQ: IONS (Ionis Pharmaceuticals, Inc.)
Kemas kini terakhir: 5 jam lalu42.93
-0.98 (-2.23%)
| Penutupan Terdahulu | 43.91 |
| Buka | 43.80 |
| Jumlah Dagangan | 3,013,739 |
| Purata Dagangan (3B) | 3,197,387 |
| Modal Pasaran | 7,134,292,992 |
| Harga / Jualan (P/S) | 10.12 |
| Harga / Buku (P/B) | 20.49 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Nov 2026 |
| Margin Keuntungan | -63.86% |
| Margin Operasi (TTM) | -111.59% |
| EPS Cair (TTM) | -2.99 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 10.10% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 413.80% |
| Nisbah Semasa (MRQ) | 9.66 |
| Aliran Tunai Operasi (OCF TTM) | -501.78 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -368.16 M |
| Pulangan Atas Aset (ROA TTM) | -10.59% |
| Pulangan Atas Ekuiti (ROE TTM) | -118.62% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Ionis Pharmaceuticals, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 5.0 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -0.5 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | NA |
| AI Insight | NA |
| Purata | 1.83 |
|
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 0.83% |
| % Dimiliki oleh Institusi | 108.17% |
Tiada data dalam julat masa ini.
AI Analisis Teknikal
Buka tab Teknikal untuk menjana analisis terkini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |